Market Newsdesk

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

      ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the protocol of the ongoing Phase II Clinical Trial in Clostridioides difficile infection

             

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance and the need for next-generation active ingredients in the service of healthcare, announces a presentation at the C.diff foundation 8th annual Virtual Conference.

Yannick Pletan, MD, MSc, HEC, Chief Medical Officer and member of the board of directors of DEINOVE will present in the “Research In Progress” virtual poster session “A Phase 2 Clinical Trial Evaluating a Novel Antibiotic Against a Clostridium difficile Infection”. He will be presenting the results of the Phase I, the protocol of the ongoing multicenter Phase II in the United States, the clinical sites, the team and the key advantages of DNV3837 antibiotic candidate: intravenous administration, precise targeting at the infection site, ability to eliminate Clostridioides bacteria without affecting the gut microbiota.

Patients enrollment is ongoing in this Phase II trial despite a disrupted context due to the COVID-19 outbreak. Preliminary results of Part I of the study are expected by S1 2021.

Video presentation is online https://youtu.be/pShknVl5kDk

ABOUT CLOSTRIDIOIDES DIFFICILE INFECTIONS (CDI)

40% of patients suffering a Clostridioides difficile infection (CDI) have severe forms, associated with high morbidity and mortality rates. Over the past 20 years, CDIs tended to increase significantly in incidence and severity, particularly due to the development of new hypervirulent strains and the high risk of recurrence. The US Center for Disease Control and Prevention (CDC) recently identified CDIs as one of the leading causes of healthcare-associated infections before Staphylococcus aureus (MRSA¹) infections. In 2017, in the United States, there were an estimated 223,900 cases in hospitalized patients and 12,800 deaths². This disease does not affect the United States only, recent studies³ show that the incidence of this type of infection is vastly underestimated in other parts of the world such as Europe and Asia.

To date, there are no therapeutic solutions for patients with severe gastrointestinal infections. Since the oral route is compromised, the available treatments, which are mostly oral treatments, struggle to reach the intestine because of the patient’s pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously (IV), do not cross the gastrointestinal barrier and therefore do not reach the site of infection.

ABOUT THE DNV3837 ANTIBIOTIC CANDIDATE

DNV3837 – a prodrug⁴ of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active 1^st line treatment targeting Clostridioides difficile.

It has demonstrated significant activity and superiority to reference treatments against isolates of C. difficile, regardless of their virulence (including the hyper virulent BI/NAP1/027 strain).

DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approx. a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. It has also shown an acceptable safety and tolerability profile.

FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status.

ABOUT THE PHASE II CLINICAL TRIAL TESTING DNV3837 IN CDI

The antibiotic candidate DNV3837 has been in a Phase II trial since the end of January 2020. The purpose of this trial is to evaluate its efficacy in CDI (through monitoring of symptoms, stool analysis, etc.), as well as to consolidate the safety and pharmacokinetic data in patients.

This trial is taking place in the United States in two stages:

• In the first part, a cohort of 10 patients with moderate to severe CDI is treated with DNV3837. At the end of this part, the DSMB⁵  has scheduled to review the interim results.
• The second part involves 30 patients with severe CDI. This is an open-label randomized trial testing DNV3837 (in 2/3 of patients) against an approved standard of care⁶ (1/3 of patients) for comparison purposes.

ABOUT DEINOVE

DEINOVE is a French biotech company, a pioneer in the exploitation of the unknown or little-known part of biodiversity.  By using rare or “non-cultivable” bacteria and by working on unexplored molecular pathways, the Company discovers, develops and produces antimicrobials to meet the urgent, global challenge of antibiotic resistance, and the need for next-generation active ingredients to serve Health.

In nearly 15 years, the Company has built a unique collection of over 10,000 bacterial strains and has developed a fully integrated technological platform that brings together the best of biological culture, synthetic biology and micro-biotechnology.

Today, DEINOVE has several development programs underway, including the antibiotic candidate   DNV3837, in a Phase II clinical trial in severe gastrointestinal infections with Clostridioides difficile, a real therapeutic challenge. Through its other program AGIR (Antibiotics against Resistant Infectious Germs), supported by Bpifrance, it is also continuing its exploration of biodiversity to supply its portfolio with new molecules. It relies on its own biodiversity and on the one entrusted to it by other specialists in the field.

DEINOVE has also developed and brought to market four particularly innovative active ingredients: a first which is phytoene-based and a neurosporene concentrate produced by Deinococcus geothermalis, as well as two cell extracts developed in collaboration.

DEINOVE, located in the Euromédecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally. It is listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056).

CONTACTS

Investors Mario Alcaraz Chief Financial and Administrative Officer Phone: +33 (0)4 48 19 01 00 [email protected]   Media ALIZE RP – Caroline Carmagnol Phone: +33 (0)6 64 18 99 59 [email protected]

 

---

¹ MRSA: meticillin-resistant Staphylococcus aureus

² https://www.cdc.gov/drugresistance/biggest-threats.html#cdiff

³ Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, and Nair H (2019) Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health 9:010407

⁴ Prodrug: substance whose transformation in the body results in an active product

⁵ DSMB – Data Safety Monitoring Board: a group of independent experts tasked to review the data generated during the trial and make recommendations on patient safety as well as trial relevance and validity.

⁶ Standard treatments approved in the United States for the treatment of CDIs include vancomycin, fidaxomicin and metronidazole (all three antibiotics). The choice will be at the discretion of the clinicians. 

Attachment

• PR in English

BOCA RATON, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — MiX Telematics (NYSE: MIXT; JSE: MIX), a leading global SaaS provider of connected fleet management solutions, announced today that it will present a webinar titled, “7 Steps To Get Started Monitoring and Modifying Driver Behavior.” The event, hosted by Heavy Duty Trucking magazine, will take place Nov 17, 2020 at 2pm ET.

According to the FMCSA, in 2017 (latest figures available), 4,889 large trucks and buses were involved in fatal crashes, a 9 percent increase from 2016. The critical pre-crash event for 73 percent of the large trucks in fatal crashes was another vehicle, person, animal, or object in the large truck’s lane or encroaching into it.

While truck drivers were not always at fault in these crashes, driver behavior certainly plays a role. Behaviors such as speeding and tailgating often contribute to crashes, or to a driver’s ability to avoid a crash even when he/she isn’t responsible for the pre-crash event.

In this event, we’ll discuss how to get started monitoring and modifying driver behavior through telematics. Attendees will learn:

• How ELDs already provide fleets with most of the data they need to begin
• Key steps to take before you start a program
• Best practices for sharing data with drivers
• How to use pulse learning to keep safe driving skills fresh

To register for this free event, visit https://event.webcasts.com/starthere.jsp?ei=1382687&Sti=Webinars.

About MiX Telematics

MiX Telematics is a leading global provider of fleet and mobile asset management solutions, delivered as SaaS, to more than more than three quarters of a million subscribers in over 120 countries. In the U.S., MiX Telematics offers a broad range of solutions; from self-service telematics software that runs on any mobile device to enterprise solutions that are ELD compliant and include dedicated account managers who proactively monitor to ensure that customers achieve optimal value for their investment. The company provides solutions for efficiency, safety, compliance and security to fleets of all sizes. MiX Telematics was founded in 1996 and has offices in the United States, South Africa, the United Kingdom, Uganda, Brazil, Mexico, Australia and the United Arab Emirates as well as a network of more than 130 fleet partners worldwide. MiX Telematics shares are publicly traded on the New York Stock Exchange (NYSE: MIXT) and the Johannesburg Stock Exchange (JSE: MIX). For more information, visit www.mixtelematics.com. 

For further information:

Michelle Faulkner
Big Swing Communications
+1 617-510-6998
[email protected]

CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced that it ranked Best in Class among 26 vendors evaluated on the Identity Proofing Platform Scorecard by research and advisory firm, Javelin Strategy & Research.

“This designation validates our efforts to unite personal and digital data,” said Bala Kumar, vice president of product for TransUnion Global Fraud Solutions. “It is our mission to continue to lead the industry in innovation to help businesses verify consumer identities, reduce the number of challenges consumers experience through more precise results and ultimately convert more transactions while keeping fraud low.”

Javelin evaluated vendors that provide enterprise-wide identity proofing solutions to financial institutions. The scorecard assessed six identity-proofing components – identity validation, identity verification, enrollment, binding, authentication and step-up authentication.

IDVision


with iovation
offers a comprehensive view of each consumer by linking proprietary data, personal data, device identifiers, and online behaviors. Its advanced insights and global network of reported fraud helps businesses discover anomalies, assess risk, and confidently identify good consumers, resulting in the ability to offer personalized, friction-right experiences.

Learn more about TransUnion being named Best in Class.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company that makes trust possible in the modern economy. We do this by providing a comprehensive picture of each person so they can be reliably and safely represented in the marketplace. As a result, businesses and consumers can transact with confidence and achieve great things. We call this Information for Good.®

TransUnion Global Fraud Solutions unite both consumer and device identities to detect threats across markets while ensuring friction-right user experiences. The solutions, all part of the IDVision with iovation suite, fuse traditional data science with machine learning to provide businesses unique insights about consumer transactions, safeguarding tens of millions of transactions each day.

A leading presence in more than 30 countries across five continents, TransUnion provides solutions that help create economic opportunity, great experiences and personal empowerment for hundreds of millions of people.
http://www.transunion.com/business

Contact		Dave Blumberg
		TransUnion
E-mail		[email protected]
Telephone		312-972-6646

 

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:

• 
  Cancer Genetics, Inc. (
  
  
  NASDAQ:
  
  
  CGIX
  
  
  )
  
  

A registration statement was recently filed with the SEC regarding StemoniX’s acquisition of Cancer Genetics. Under the proposed transaction, Cancer Genetics will issue shares of common stock to the owners of StemoniX, with current holders of Cancer Genetics common stock controlling only 22% of the combined company. The investigation concerns whether Cancer Genetics’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price.

• 
  Concho Resources Inc.
  
  
  (
  
  
  NYSE
  
  
  :
  
  
  CXO
  
  
  )
  
  

Concho Resource has agreed to be acquired by ConocoPhillips. Under the proposed transaction, shareholders of Concho will receive 1.46 shares of ConocoPhillips per share.

• 
  Cellular Biomedicine Group, Inc.
  
  
  (
  
  
  NASDAQ:
  
  
  CBMG
  
  
  )
  
  

Cellular Biomedicine has agreed to be acquired by consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned.

• 
  Front Yard Residential Corporation
  
  
  (
  
  
  N
  
  
  YSE
  
  
  :
  
  
  RESI
  
  
  )
  
  

Front Yard Residential has agreed to be acquired by Pretium and a group of its investors and funds. Under the proposed transaction, shareholders of Front Yard will receive $13.50 per share.

Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at [email protected] or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Moore Kuehn is a 5-star New York City-based law firm with attorneys representing investors and consumers in class action litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8^th Floor
New York, New York 10005
[email protected]
(212) 709-8245

New York City, Nov. 12, 2020 (GLOBE NEWSWIRE) — Now that the campaign is over, it’s time to take stock and distill the lessons to be learned. President-Elect Biden promises to unite the country. After this election, is that even possible?  Join us Friday morning at 11 am ET for this free webinar.

That said, join Michael Zeldin in his conversation with The Washington Post Chief Correspondent Dan Balz as they break down last week’s election and discuss how Joe Biden won and the specific challenges that await the Biden administration and the country more broadly.  What message does this send about the United States on the global stage?  What is the impact on main street and Wall Street?

Reserve your free spot for this webinar: http://sumo.ly/14xAl

Contact:

Fay Shapiro

Email: [email protected]

Phone: 212.779.0181

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Epiq, a global leader in the legal services industry, announced today that it is has acquired Hyperion Global Partners (Hyperion), the premier global business and technology advisory practice for legal operations and transformation.

The acquisition expands Epiq’s strategy to deliver a suite of legal business management services and solutions to corporate in-house law departments, law firms and other clients. Hyperion’s founder and CEO, Eyal Iffergan, will join Epiq as Managing Director of its new legal operations advisory business.  

The Hyperion acquisition includes its legal operations advisory practice as well as Hyperion Research, the analyst-driven unit of Hyperion Global Partners focused on legal solutions market intelligence. Hyperion Research is the premier provider of independent market research and analysis, delivering unparalleled insights on leading trends in legal strategy, operations and technology.

“The recent pace of legal industry change has acutely accelerated the need for law departments and firms to be run like a business, including the need to embrace digital transformation,” said Ziad Mantoura, SVP and General Manager for Epiq’s legal transformation services business. “Hyperion has a team of expert consultants and a heritage of guiding clients to make intelligent, fact-based decisions to transform their businesses. Joining forces with this team and its impressive market intelligence capabilities adds considerable depth to the solutions we offer our clients as we help guide their digital transformation.”

Hyperion’s Iffergan remarked, “Hyperion has long been recognized for our drive to deliver operational expertise and innovation, with a healthy dose of pragmatism, to help our clients execute legal operations transformation programs. Our integration with Epiq, the globally recognized leader in legal business operations and services, brings together a powerhouse of capabilities and scale – a dynamic professional toolkit to galvanize our clients’ keystone initiatives and empower legal teams everywhere to achieve operational performance excellence.”

The legal transformation services group at Epiq was launched earlier this year and is part of its Legal Solutions business, led by Roger Pilc, President and General Manager. Hyperion’s capabilities complement Epiq’s services, which in addition to law department and law firm consulting, includes eDiscovery, legal spend analysis, flexible legal talent, and information governance.

Said Pilc, “We’re thrilled to have Hyperion as part of Epiq as we continue to build out our vision for helping our clients. “Together, we can scale and extend their transformative work with legal teams globally.”  

About
Hyperion Global Partners

Founded in 2009, Hyperion Global Partners is recognized as the premier global business and technology consulting practice for the legal profession. Hyperion Global Partners brings over twenty years of dedicated experience in legal business, operations and technology solutions. We advise Am Law 200 law firms, Global 1000 corporations and other legal service organizations to make intelligent, fact-based decisions about how to improve their operational performance. A consultancy of experts, we focus on helping our clients lead transformation programs with strategic value-based engagement models and legal business expertise in process, operations, organization and technology. For more information, please visit www.hyperiongp.com.

About Epiq

Epiq, a global leader in the legal services industry, takes on large-scale, increasingly complex tasks for corporate counsel, law firms, and business professionals with efficiency, clarity, and confidence. Clients rely on Epiq to streamline the administration of business operations, class action and mass tort, court reporting, eDiscovery, regulatory, compliance, restructuring, and bankruptcy matters. Epiq subject-matter experts and technologies create efficiency through expertise and deliver confidence to high-performing clients around the world. Learn more at www.epiqglobal.com.

Press Contact

Catherine Ostheimer
[email protected]
+1 203 921 9700

Philadelphia, PA, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire –Pennexx has released more details about Pennexx’s increasing revenue and products.

Pennexx is building a strong foundation for its company and part of that is building a strong board of directors. Vincent Risalvato is proposing two candidates who have agreed to take a board seat if elected; they are Joseph Caruso and Phillip Welch.

Joseph Caruso https://evestigate.com/joseph-caruso has a long history of startup business success and is a recognized industry leader in the fields of cyber security, computer forensics and eDiscovery. He has been featured as a technology expert regarding high profile cases on CNN Headline News, CBS Evening News with Katie Couric, FOX Business’s Varney and Company.

Phillip Welch is a Certified Microsoft Systems Expert, was director of IT for a national broadcast television network and has for nearly 20 years provided managed IT services for hundreds of customers as President and CEO of https://welchandcompany.net. His background in both technology and the operational aspects of many multi-million dollar businesses makes him well suited to help guide Pennexx to success.

Both gentlemen have worked closely with Vincent Risalvato over many years and are excited to possibly join the board, bringing great value to $PNNX.

Any nominations for board members can be emailed to [email protected] for review. Pennexx is considering adding two other new candidates to the board for a total of five board directors.

Vincent Risalvato said, “By growing a strong board of directors with exciting candidates we take the next step in the evolution of Pennexx. They can guide the company to success as well as open many doors.”

Pennexx will be uploading to OTC Markets a formal business plan which include the overall going forward strategy of the company and revenue estimates for the first time. The company will also be outlining its strategy for becoming fully audited.

Vincent Risalvato said, “Becoming an audited company was a goal that I had early on, one that slipped from our sights as development progressed and as the COVID pandemic set in.”

Vincent continued, “Transparency and responsibility to the shareholders is a key tenet that I have for my conduct and the conduct of the company. I wish to guide the company to achieve the goal of having an audited status. It is an important step to getting the company to a fully reporting SEC status and is one of the important steps to up listing the company.”

Pennexx is proposing to change its name by removing the word “Foods” from the name and possibly adding “Technologies”. The naming process change will require approval from the appropriate regulators.

This name change is in accordance with the fact that Pennexx is currently hosting multiple technology projects.

The company has been having great success with its ongoing development partnership projects. 

They had previously announced the development of the Cyber Security Dashboard (CSD) https://www.globenewswire.com/news-release/2020/06/11/2047010/0/en/Pennexx-Partners-With-Global-Digital-Forensics-to-Create-a-Cloud-Based-Forensic-Dashboard.html. The CSD will begin collecting subscription revenue in the fourth quarter and that profit is shared between Pennexx and Global Digital Forensics https://www.evestigate.com.

Progress on the development partnership with https://zicixgroup.com was also announced recently by Zicix https://finance.yahoo.com/news/zicix-launches-website-smartphone-app-140000861.html.

Vincent Risalvato had said previously, “By partnering on these development projects, we have started to deliver on my desire to grow the business organically (from money collected from our products and services) instead of relying solely on investment dollars. I believe best businesses grow through revenue since they become a commercial success as they develop instead of having to figure out the commercialism of their product after a large investment. This strategy can decrease potential dilution to the shareholders and increases shareholder value.”

The company is going to be reporting its third quarter financials shortly. Pennexx’s financials will still show a small income due to the fact that the focus has been on product development and its services revenue was only in its infancy.

Vincent Risalvato has indicated that the fourth quarter financials will start to show revenue generated through its development partnerships. Since Pennexx has just recently launched its new dashboard which opens up a number of revenue generating e-commerce offerings, a small amount of that revenue will also begin in the fourth quarter.

Vincent said, “Come this fourth quarter and first quarter 2021, I believe we will begin to see real quarter over quarter growth and the realization of my goal for the organic growth of the company.”

Additionally, the company is still forging forward with its YSO debit card program. Vincent Risalvato said, “I am sorry that this process has been so delayed; part of it was the onset of Covid and another part of it was just not really knowing all of the legal and technical challenges that had been laid ahead. This is a program that I feel strongly about and I remain confident that it will be a major part of the YSO/YSI program. We have a graphic design for the card and pending the approval of the card issuer we will release the mockup publicly.”  

Pennexx recognizes that these updates will unlock a number of questions and comments and they say, “We will do our best via social media to answer questions as they are posted.” They advise that the best place to ask questions is openly on twitter @pennexx. This way they can answer them openly and publicly. They continue by saying, “We may not answer all questions, but we make our best effort to answer all questions posted constructively.”

Questions may also be posted at [email protected]; many shareholders do get responses from the CEO directly when questions are emailed in. Some of them post those responses within the investor community.

It is also recommended that people follow Mr. Risalvato on Twitter at https://twitter.com/vrisalvato as he intends to start using this account for much more frequent updates.

Vincent Risalvato said, “Pennexx is at a pivotal point now in its growth where investment of money and time can now start generating revenue. It is an exciting time and I am thankful to everyone who has and continues to support the company and our success.”

About Pennexx Foods Inc.

About Pennexx Foods Inc. (PNNX: OTCMKTS US). Pennexx, through its wholly-owned subsidiaries, is a holding company within the Software/Internet Industry focused on social media, prepaid debit cards, BitGift™, artificial intelligence, targeted marketing, and consumer rewards.

Safe Harbor Act: This release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report.

For additional information, visit our website at https://yoursocialoffers.com or https://pennexx.net or call 866-928-6409. Please follow us on Twitter @Pennexx.